Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising

Exact Sciences Corporation (EXAS) recently reported a promising outcome for the non-endoscopic Oncoguard Esophagus test, developed in collaboration with the Mayo Clinic Comprehensive Cancer Center. The test, currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE), has demonstrated high sensitivity and specificity.The findings from the test’s algorithm training and testing were recently published in the Clinical Gastroenterology and ...